Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
8615791 | Clinical Lymphoma Myeloma and Leukemia | 2017 | 26 Pages |
Abstract
We conclude that outcomes for FL3, primarily treated with R-CHOP, do not differ between FL3A and aggFL (FL3B and FL3/DLBCL). The aggFL group showed a plateau in PFS confirming these should be treated with curative intent. FL3A patients, mainly managed with R-CHOP, also show an apparent plateau in PFS. Although longer follow-up and confirmation in other data sets is required, this indicates potential undertreatment of FL3A with less aggressive regimens often used for indolent lymphoma.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Anesthesiology and Pain Medicine
Authors
Moaath Mustafa Ali, Lisa Rybicki, Laila Nomani, Basel Rouphail, Robert M. Dean, Brian T. Hill, Deepa Jagadeesh, Brad Pohlman, Eric D. Hsi, Mitchell R. Smith,